CAGE1 and acute myeloid leukemia: To investigate if the ability to inhibit the MYB transactivation potential also contributes to the effects of Bcr-TMP elicited in AML cells we employed HL60 cells overexpressing MYB-CT3, a C-terminally truncated MYB that is more active than wild-type MYB [53].